1. High expression of nectin-1 indicates a poor prognosis and promotes metastasis in hepatocellular carcinoma
   Xuequan Wang et al, 2022, Frontiers in Oncology CrossRef
2. Current and Emerging Treatments for Urothelial Carcinoma: A Focus on Enfortumab Vedotin
   Muhammad Ashir Shafique et al, 2023, Cancer Management and Research CrossRef
3. The Development of Antibody-Drug Conjugates for Urothelial Carcinoma Treatment
   Da Som Choi et al, 2021, The Korean Journal of Urological Oncology CrossRef
4. Antibody-drug conjugates and predictive biomarkers in advanced urothelial carcinoma
   Sarah E. Fenton et al, 2023, Frontiers in Oncology CrossRef
5. A Specificity Protein 1 assists the Progression of the Papillary Thyroid Cell Line by Initiating NECTIN4
   Jie Chen et al, 2024, Endocrine, Metabolic & Immune Disorders - Drug Targets CrossRef
6. Discovery of BT8009: A Nectin-4 Targeting Bicycle Toxin Conjugate for the Treatment of Cancer
   Gemma E. Mudd et al, 2022, Journal of Medicinal Chemistry CrossRef
7. Nectin-4 is widely expressed in head and neck squamous cell carcinoma
   Christine Sanders et al, 2022, Oncotarget CrossRef
8. Enfortumab Vedotin-ejfv: A First-in-Class Anti–Nectin-4 Antibody-Drug Conjugate for the Management of Urothelial Carcinoma
   Zachery Halford et al, 2021, Annals of Pharmacotherapy CrossRef
9. Prognostic value of nectin-4 in human cancers: A meta-analysis
   Rongqiang Liu et al, 2023, Frontiers in Oncology CrossRef